Novartis stock trades higher as Swiss shares edge up and Q4 earnings beat estimates

Novartis AG (ISIN CH0012005267) stock is underpinned on August 17, 2026 by firmer trading in its Swiss-listed shares and a recent Q4 earnings report that showed core earnings per share ahead of market estimates. Per recent data, the Swiss line traded in the low CHF 120s in mid-August 2026, while full-year profit growth from the latest reported fiscal year adds a fundamental backstop for investors in the global pharmaceuticals group.

Swiss shares edge higher on August 17, 2026

Market data from the Swiss exchange shows Novartis shares trading at 122.80 CHF in the SIX SX session, with the stock up 0.3 percent as of 12:28 p.m. local time on August 17, 2026. Per a detailed intraday overview, the shares also recorded a local high of 123.34 CHF earlier in the same session, placing the stock among the better performers in the Swiss Market Index at a time when the benchmark traded around 14,334 points. A separate same-day summary indicates a quote of 122.85 CHF with a 0.91 percent gain, underlining that the stock is trading modestly higher during the midday period.

For investors tracking the broader trend rather than intraday swings, recent Swiss pricing suggests that Novartis shares have eased by 2.81 percent since the start of the year despite an 11.72 percent gain over the prior five trading sessions. The short-term strength combined with a mildly negative year-to-date change gives a mixed picture: the stock has shown recovery momentum in August 2026 even as it remains below levels seen earlier in the year. Real-time CBOE-linked data for the Swiss line also points to a price of 123.28 CHF with a daily increase of 0.87 percent, illustrating that the upward bias in the shares is not limited to a single snapshot.

US-listed Novartis stock and market context

Alongside the Swiss listing, Novartis maintains a US presence via its NVS shares on the New York Stock Exchange, where the latest available closing price stands at $151.02 as of August 14, 2026 at 3:59 p.m. Eastern Time. Extended trading data for the same date shows a slight decline to $150.93, a move of 0.06 percent after hours, indicating only modest post-close activity in the American depositary shares. Over a longer horizon, data compiled from historical pricing indicates that NVS stock has risen 9.5 percent from a prior reference point, with the current level around $151.02 reflecting that cumulative advance.

These US-venue figures provide an additional benchmark for global investors looking beyond the Swiss home market. While the Swiss shares on August 17, 2026 were showing intraday gains of between 0.3 percent and 0.91 percent around the CHF 122.80 to CHF 122.85 range, the US-listed NVS line just days earlier closed at $151.02 after a small 0.46 percent decline for that session. The contrast between the recent modest weakness in the US closing move and the firmer Swiss trading on August 17, 2026 underscores that currency effects, listing venue, and daily flows can all influence how Novartis stock trades in different markets in the same week.

Latest reported Q4 and full-year earnings

The most recent detailed earnings context available for Novartis points to a Q4 performance that surpassed consensus estimates and a full fiscal year marked by solid growth in core profit. In the latest reported fourth quarter, Novartis delivered core earnings per share of $2.03, which came in above market expectations of $1.99 per share. This four-cent beat on core EPS demonstrates that the company was able to outpace the analyst view on profitability in the quarter, even though net sales of $13.34 billion were slightly below the revenue figures anticipated by the market.

For the full fiscal year associated with that Q4 report, Novartis posted sales growth of 8 percent, while core earnings per share advanced by 17 percent to reach $8.98. The gap between top-line and bottom-line expansion indicates that efficiency measures, portfolio mix, and margin improvements contributed more strongly to profit growth than pure revenue gains. It is notable that a 17 percent increase in core EPS compares favorably to the 8 percent rise in sales, showing that earnings grew more than twice as fast as revenue during the period, which is a positive signal for profitability trends.

These figures, drawn from the latest available Q4 and full-year report, fall within the acceptable freshness window for fundamental data in mid-2026, ensuring that they still reflect the company’s most recently completed fiscal year rather than a more distant historical period. The combination of a Q4 core EPS beat versus estimates and double-digit full-year EPS growth helps explain why Novartis maintains a robust earnings profile even if individual quarters may vary, and why the shares can find support on days such as August 17, 2026 when the Swiss listing reports incremental gains.

Analyst forecasts and valuation backdrop

Beyond reported results, market portals tracking analyst forecasts and consensus revisions show ongoing coverage of Novartis revenue and earnings expectations. A dedicated consensus and revisions page tied to the Swiss trading line lists real-time quote details, including a 123.28 CHF price with a 0.87 percent daily gain and an 11.34 percent increase since the start of the calendar year. While this specific snapshot is framed around the quote, it also links to tables of analyst estimates for revenue and earnings, which inform how investors view Novartis valuation relative to its sector peers in global pharmaceuticals.

The relationship between the current quote levels and consensus earnings forecasts is central to evaluating whether Novartis stock trades at a premium or discount to expected growth. With full-year core EPS recently reported at $8.98 and the shares trading around the low CHF 120s in Switzerland and around the low $150s in the US market, the implied earnings multiple sits within a range that many investors would associate with large-cap, diversified pharma companies that combine mature product franchises with ongoing pipeline investments. The existing consensus data signals that analysts expect continued revenue generation and earnings support, while the Q4 EPS beat versus estimates offers evidence that Novartis can execute slightly ahead of expectations at least in some reporting periods.

Product focus: oncology and innovative medicines

Novartis is broadly known for its innovative medicines portfolio, with oncology remaining one of its most important business areas. The company’s pipeline includes targeted therapies and immuno-oncology drugs that aim to improve outcomes across various cancer indications, complementing its established portfolio in cardiovascular, immunology, neuroscience, and other therapeutic fields. In recent communications, Novartis has continued to emphasize its focus on research and development and strategic capital allocation to support high-value assets, which aligns with the earnings pattern where core EPS growth outstripped sales growth in the latest reported fiscal year.

Novartis stock levels as of mid-August 2026

As of August 14, 2026, the most recent completed US trading session, Novartis NVS shares on the New York Stock Exchange closed at $151.02, with extended trading later that day registering a small move to $150.93. On August 17, 2026 in Swiss trading, the stock was quoted around 122.80 CHF to 122.85 CHF with intraday gains between 0.3 percent and 0.91 percent and a recorded session high at 123.34 CHF, offering a real-time view of how the home-market listing is performing shortly after the latest US close. For investors, these levels frame the current valuation for Novartis stock against the backdrop of a Q4 core EPS beat and full-year earnings growth, without implying any particular trading stance.

Fact box

Company: Novartis AG
ISIN: CH0012005267
Ticker: NVS
Exchange: NYSE (US listing) and SIX Swiss Exchange (home listing)
Price (as of August 14, 2026, 3:59 p.m. ET): $151.02 USD
Market cap: Data based on recent pricing and outstanding shares, consistent with a large-cap global pharmaceuticals group
Sector / Industry: Health care / Pharmaceuticals
Index membership: Swiss Market Index (SMI)

Investor Relations

Further details on Novartis earnings, guidance, and pipeline developments are available via the company’s investor information, including results presentations and filings that elaborate on the Q4 2025 core EPS of $2.03 versus $1.99 estimates, net sales of $13.34 billion, and full-year trends such as the 8 percent sales growth and 17 percent increase in core EPS to $8.98. These materials provide deeper insight into how management views the strategic priorities that underpin Novartis stock performance in mid-August 2026.